Novo Nordisk/$NVO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Novo Nordisk
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Ticker
$NVO
Sector
Primary listing
NYSE
Industry
Pharmaceuticals
Headquarters
Bagsvaerd, Denmark
Employees
77,406
ISIN
US6701002056
Website
Novo Nordisk Metrics
BasicAdvanced
$343B
21.16
$3.64
0.21
$1.18
2.13%
Price and volume
Market cap
$343B
Beta
0.21
52-week high
$148.15
52-week low
$57.00
Average daily volume
11M
Dividend rate
$1.18
Financial strength
Current ratio
0.739
Quick ratio
0.542
Long term debt to equity
69.518
Total debt to equity
85.696
Dividend payout ratio (TTM)
48.61%
Interest coverage (TTM)
41.95%
Profitability
EBITDA (TTM)
24,072.281
Gross margin (TTM)
84.65%
Net profit margin (TTM)
34.51%
Operating margin (TTM)
48.43%
Effective tax rate (TTM)
20.93%
Revenue per employee (TTM)
$607,670
Management effectiveness
Return on assets (TTM)
23.29%
Return on equity (TTM)
88.12%
Valuation
Price to earnings (TTM)
21.162
Price to revenue (TTM)
7.292
Price to book
15.96
Price to tangible book (TTM)
75.83
Price to free cash flow (TTM)
29.726
Free cash flow yield (TTM)
3.36%
Free cash flow per share (TTM)
259.10%
Dividend yield (TTM)
1.53%
Forward dividend yield
2.13%
Growth
Revenue change (TTM)
24.11%
Earnings per share change (TTM)
17.93%
3-year revenue growth (CAGR)
26.70%
10-year revenue growth (CAGR)
12.46%
3-year earnings per share growth (CAGR)
29.74%
10-year earnings per share growth (CAGR)
15.18%
3-year dividend per share growth (CAGR)
29.91%
10-year dividend per share growth (CAGR)
16.38%
What the Analysts think about Novo Nordisk
Analyst ratings (Buy, Hold, Sell) for Novo Nordisk stock.
Bulls say / Bears say
Novo Nordisk reported a 26% increase in net sales to DKr290bn ($40bn) in 2024, driven by strong demand for its obesity drugs like Wegovy, indicating robust financial health and market demand. (ft.com)
The company has secured insurance coverage for Wegovy for 55 million Americans and expanded its launch to over 15 countries, enhancing its global market presence. (ft.com)
Novo Nordisk's acquisition of three manufacturing facilities from Catalent for $11 billion aims to scale up production to meet the massive demand for Wegovy and Ozempic, potentially boosting future revenues. (en.wikipedia.org)
The company downgraded its 2025 sales and profit outlook due to slowing Wegovy obesity drug sales, marking the first decrease in forecasts since the product's launch. (reuters.com)
CEO Lars Fruergaard Jorgensen is stepping down following a sharp decline in the firm’s share price and downgraded financial forecasts, indicating potential instability in leadership. (apnews.com)
Eli Lilly's weight loss drug Zepbound now surpasses Wegovy in U.S. prescriptions, raising concerns about Novo Nordisk losing market leadership in the obesity treatment sector. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2025.
Novo Nordisk Financial Performance
Revenues and expenses
Novo Nordisk Earnings Performance
Company profitability
Novo Nordisk News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Novo Nordisk stock?
Novo Nordisk (NVO) has a market cap of $343B as of June 18, 2025.
What is the P/E ratio for Novo Nordisk stock?
The price to earnings (P/E) ratio for Novo Nordisk (NVO) stock is 21.16 as of June 18, 2025.
Does Novo Nordisk stock pay dividends?
Yes, the Novo Nordisk (NVO) stock pays dividends to shareholders. As of June 18, 2025, the dividend rate is $1.1814 and the yield is 2.13%. Novo Nordisk has a payout ratio of 48.61% on a trailing twelve-month basis.
When is the next Novo Nordisk dividend payment date?
The next Novo Nordisk (NVO) dividend payment date is unconfirmed.
What is the beta indicator for Novo Nordisk?
Novo Nordisk (NVO) has a beta rating of 0.21. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.